Revance Therapeutics, Inc. Provides RHA® Collection Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2021
For the full year, the company expects unaudited RHA® Collection revenue of between $70.0 million and $71.0 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.425 USD | +3.63% | -15.51% | -72.41% |
1st Jan change | Capi. | |
---|---|---|
-72.41% | 24Cr | |
+2.97% | 9.47TCr | |
-3.68% | 3.73TCr | |
-11.63% | 3.27TCr | |
+74.21% | 2.77TCr | |
-14.15% | 1.62TCr | |
-2.29% | 1.39TCr | |
-12.21% | 1.16TCr | |
+188.83% | 1.09TCr | |
-53.94% | 954.09Cr |